PILOT STUDY FOR IDENTIFYING URINARY PROSTATE CANCER BIOMARKERS

$28,669P41FY2011RRNIH

Battelle Pacific Northwest Laboratories, Richland WA

Investigators

Linked publications, trials & patents

Paper 37473758 Paper 29899368 Paper 28810879 Paper 28538182 Paper 27165815 Paper 26185483 Paper 25855118 Paper 25813043 Paper 25284785 Paper 25266362 Paper 25192788 Paper 25089116 Paper 24691437 Paper 24676894 Paper 24642900 Paper 24586154 Paper 24555535 Paper 24440233 Paper 24115015 Paper 24039694 Paper 24002365 Paper 23970565 Paper 23943280 Paper 23935562 Paper 23720318 Paper 23649778 Paper 23639857 Paper 23637642 Paper 23599423 Paper 23589343 Paper 23507713 Paper 23495885 Paper 23477683 Paper 23409944 Paper 23398735 Paper 23396917 Paper 23363978 Paper 23303698 Paper 23277452 Paper 23268687 Paper 23242617 Paper 23217253 Paper 23176123 Paper 23147219 Paper 23142082 Paper 23115268 Paper 23110155 Paper 23049804 Paper 23034525 Paper 23019139 Paper 22949669 Paper 22943415 Paper 22936678 Paper 22900174 Paper 22889348 Paper 22886542 Paper 22865858 Paper 22846433 Paper 22843990 Paper 22840822 Paper 22815360 Paper 22759378 Paper 22735334 Paper 22718821 Paper 22709424 Paper 22663564 Paper 22580588 Paper 22578083 Paper 22577010 Paper 22565507 Paper 22559289 Paper 22559202 Paper 22546282 Paper 22522136 Paper 22517741 Paper 22509832 Paper 22498958 Paper 22479638 Paper 22479471 Paper 22462785 Paper 22433316 Patent 9245725 Patent 8299443 Patent 8277659 Patent 8263930 Patent 8173960 Patent 8061187 Patent 7888635 Patent 7816645 Patent 7756646 Patent 7671344 Patent 7541576 Patent 7514676 Patent 7491930 Patent 7491341 Patent 7351964 Patent 7339166 Patent 7170053 Patent 7148474 Patent 7136759

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Urinary prostate cancer protein biomarkers are important for early cancer detection. A urine test at this point can significantly reduce the number of unnecessary biopsies done as a result of elevated serum PSA. The application of genomics to cancer cells has allowed the identification of a number of candidate biomarkers for further investigations. This pilot study will utilize the advanced targeted proteomic technology using multiple reaction monitoring (MRM) under the resource center for testing the discriminatory power of identified cancer proteins in urine samples. The application is also anticipated to drive further development and optimization of the targeted MRM technology.

View original record on NIH RePORTER →